Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans
Tessa de Vries, Carlos M. Villalón, Antoinette MaassenVanDenBrink
Pharmacology & Therapeutics (2020) Vol. 211, pp. 107528-107528
Closed Access | Times Cited: 159

Showing 1-25 of 159 citing articles:

Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles
Heidi Hautakangas, Bendik S. Winsvold, Sanni Ruotsalainen, et al.
Nature Genetics (2022) Vol. 54, Iss. 2, pp. 152-160
Open Access | Times Cited: 256
CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond
Andrew F. Russo, Debbie L. Hay
Physiological Reviews (2022) Vol. 103, Iss. 2, pp. 1565-1644
Open Access | Times Cited: 162
Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis
Roberta Messina, Eva‐Maria Huessler, Francesca Puledda, et al.
Cephalalgia (2023) Vol. 43, Iss. 3
Open Access | Times Cited: 76
European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure
Simona Sacco, Christian Lampl, Faisal Mohammad Amin, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 73
Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2’-O-Methylation of Viral RNA
José Antonio Encinar, Javier A. Menéndez
Viruses (2020) Vol. 12, Iss. 5, pp. 525-525
Open Access | Times Cited: 93
The NLRP3 inflammasome: an emerging therapeutic target for chronic pain
Ruixiang Chen, Chengyu Yin, Jianqiao Fang, et al.
Journal of Neuroinflammation (2021) Vol. 18, Iss. 1
Open Access | Times Cited: 91
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study
Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
European Journal of Neurology (2021) Vol. 29, Iss. 4, pp. 1198-1208
Closed Access | Times Cited: 56
Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine
Hannah A. Blair
CNS Drugs (2023) Vol. 37, Iss. 3, pp. 255-265
Open Access | Times Cited: 28
Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies
Irene de Boer, Iris E. Verhagen, Marcio Nattan Portes Souza, et al.
Cephalalgia (2023) Vol. 43, Iss. 2
Open Access | Times Cited: 23
Rare variants with large effects provide functional insights into the pathology of migraine subtypes, with and without aura
Gyða Björnsdóttir, Mona Ameri Chalmer, Lilja Stefánsdóttir, et al.
Nature Genetics (2023) Vol. 55, Iss. 11, pp. 1843-1853
Open Access | Times Cited: 23
Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials
Xinxin Deng, Liying Zhou, Cui Liang, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 9
Bridging Gaps in Migraine Management: A Comprehensive Review of Conventional Treatments, Natural Supplements, Complementary Therapies, and Lifestyle Modifications
Fatma Abo-Elghiet, Heba Elosaily, Doha K. Hussein, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 139-139
Open Access | Times Cited: 1
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Wen‐Jing Xiao, Wenjie Jiang, Zheng Chen, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine—The monoclonal antibodies and gepants
Chia‐Chun Chiang, Todd J. Schwedt
Progress in brain research (2020), pp. 143-170
Closed Access | Times Cited: 61
Atogepant: First Approval
Emma D. Deeks
Drugs (2021) Vol. 82, Iss. 1, pp. 65-70
Closed Access | Times Cited: 42
Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database
Alexandre O. Gérard, Diane Merino, Elise K. Van Obberghen, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 33
Neurogenic inflammation as a novel treatment target for chronic pain syndromes
Matthias F. Seidel, Thomas Hügle, Bart Morlion, et al.
Experimental Neurology (2022) Vol. 356, pp. 114108-114108
Open Access | Times Cited: 29
Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan
Shiho Suzuki, Keisuke Suzuki, Tomohiko Shiina, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 17
Sex differences in CGRP-induced vasodilation of human middle meningeal arteries but not human coronary arteries: implications for migraine
Tessa de Vries, Deirdre M. Boucherie, Kayi Y. Chan, et al.
Cephalalgia (2024) Vol. 44, Iss. 7
Closed Access | Times Cited: 6
Antagonism of CGRP Signaling by Rimegepant at Two Receptors
Kylie S. Pan, Andrew Siow, Debbie L. Hay, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 47
Crosstalk between skeletal and neural tissues is critical for skeletal health
Nethmi Abeynayake, Agnieszka Arthur, Stan Gronthos
Bone (2020) Vol. 142, pp. 115645-115645
Open Access | Times Cited: 45
CGRP inhibitors for migraine prophylaxis: a safety review
Eduardo Rivera‐Mancilla, Carlos M. Villalón, Antoinette MaassenVanDenBrink
Expert Opinion on Drug Safety (2020) Vol. 19, Iss. 10, pp. 1237-1250
Open Access | Times Cited: 42
Global prevalence and pathogenesis of headache in COVID-19: A systematic review and meta-analysis
Endang Mutiawati, Syahrul Syahrul, Marhami Fahriani, et al.
F1000Research (2020) Vol. 9, pp. 1316-1316
Open Access | Times Cited: 41
Are 5-HT1 receptor agonists effective anti-migraine drugs?
Masaru Tanaka, Nóra Török, László Vécsei
Expert Opinion on Pharmacotherapy (2021) Vol. 22, Iss. 10, pp. 1221-1225
Open Access | Times Cited: 39
Brain barriers and their potential role in migraine pathophysiology
Astrid Wiggers, Håkan Ashina, Nouchine Hadjikhani, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top